Catheter Ablation of Atrial Fibrillation Has Become the Prime Therapy for Most Patients with Atrial Fibrillation. Proponent: Roger A.
|
|
- Helen Hodges
- 6 years ago
- Views:
Transcription
1 Catheter Ablation of Atrial Fibrillation Has Become the Prime Therapy for Most Patients with Atrial Fibrillation Proponent: Roger A. Winkle Disclosures Investigator for Cardiorobotics Investigator for CABANA trial Investigator Medtronic MelScheinerone is not FDA approved I have no financial interest in MelScheinerone Questions 1. I believe in Afib ablation and it is my treatment of choice for symptomatic patients 2. I like the idea of Afib ablation but there are too many complications 3. I like the idea of Afib ablation but it does not cure enough patients to make it worthwhile 4. I like the idea of Afib ablation but there are too many complications and it does not cure enough patients 5. I don t like the idea of Afib ablation 1
2 Future Afib Ablator Atrial Fibrillation is Bad! Symptoms are present in almost all patients Worsens most patient s QOL Increases stroke risk substantially Results in multiple hospitalizations and medical encounters Increases mortality Makes patients fatter and wears out their hearts 2
3 Palpitations Chest pain Dyspnea Syncope, dizzy spells Fatigue Other None Lévy et al. Circulation 1999;99: Type of Symptoms Wolf et al: Arch Int Med: 1987: 147; " 3
4 Framingham Heart Study: Percent of Men and Women Dead with and without AF (ages 55-74) Adjusted for age, BP, smoking," diabetes, LVH, MI, CHF, valve disease, " CVA and TIA" (Benjamin et al Circ 1998;98: )" Framingham Heart Study: Percent of Men and Women Dead with and without AF (ages 75-94) Adjusted for age, BP, smoking," diabetes, LVH, MI, CHF, valve disease, " CVA and TIA" (Benjamin et al Circ 1998;98: )" 4
5 Early Termination of Persistent AF and Ablation Outcomes (Winkle et. Al. AJC 1011;108: ) Persistent AF (AF2) AF2a: 179 patients whose physicians always terminated persistent AF by drugs or CV in < 1 week Compared to AF2b: 244 patients left in persistent AF for > 1 week up to 1 year 5
6 Early Termination of Persistent Atrial Fibrillation is Associated with Smaller Left Atrial Size and Better Ablation Outcomes (Winkle et. Al. AJC 1011;108: ) Early Termination of Persistent Atrial Fibrillation is Associated with Smaller Left Atrial Size and Better Ablation Outcomes (Winkle et. Al. AJC 1011;108: ) 6
7 Early Termination of Persistent Atrial Fibrillation: Clinical Variables (Winkle et. Al. AJC 1011;108: ) AF2a AF always terminated AF2b AF >1 week < 1year P Value Number 179 (42.3%) 244 (57.7%) LA size (cm) < * Age (years) =0.194 Females 29.1% 22.5% = DuraNon of AF (years) = * # Drugs Failed = * Average CHADS score = Hypertension 44.1% 50.0% = Diabetes 7.3% 9.0% = BMI = * Cardioversions 65.9% 69.7% = % Redo ablanons 34.1% 30.3% = Coronary artery disease 12.8% 17.2% = Dilated cardiomyopathy 3.9% 11.1% = 0.010* Prior Stroke/TIA 6.1% 6.1% = * StaNsNcally significant Early Termination of Persistent Atrial Fibrillation is Associated with Smaller Left Atrial Size and Better Ablation Outcomes (Winkle et. Al. AJC 1011;108: ) 7
8 Rate control is not the answer! Multiple studies compare rate control to rhythm control using AADs Rate control does nothing to reduce the stroke risk The drugs for rate control cause side effects and even death (digoxin) Due to poor AAD efficacy and crossovers the studies may not really show what they claim AADs may be so toxic that they wipe out any benefit of NSR Atrial Fibrillation Follow-Up Investigation of Rhythm Management-The AFFIRM Study Design (AFFIRM Investigators. NEJM 2002;347: ) Enrolled 4060 patients Patients with atrial fibrillation and high risk of stroke All patients on anticoagulation with target INR = 2.5 (range ) Randomized to initial strategy of rate control or attempts to maintain NSR Primary endpoint: Total Mortality Intention to treat analysis 8
9 Atrial Fibrillation Follow-Up Investigation of Rhythm Management-The AFFIRM Study Design (AFFIRM Investigators. NEJM 2002;347: ) Hypothesis: Antiarrhythmic therapy to maintain NSR has no effect on total mortality compared with therapy that controls the heart rate Enrolled 4060 patients Primary endpoint: Total Mortality Secondary endpoints mortality + CVA s mortality + CVA s + cardiac arrest cost quality of life Intention to treat analysis Atrial Fibrillation Follow-Up Investigation of Rhythm Management-The AFFIRM Study Design (AFFIRM Investigators. NEJM 2002;347: ) Patients with atrial fibrillation and high risk of stroke > 65 years old < 65 years old and > 1 other risk factor (hypertension, diabetes, CHF, TIA, prior CVA, LA > 50mm, fractional shortening < 25%, LVEF< 40%) All patients on anticoagulation with target INR = 2.5 (range ) All patients may have one initial successful cardioversion Randomized to initial strategy of rate control or attempts to maintain NSR 9
10 The Unfortunate Saga of MelScheinerone 5000 patients at high risk of CV death 2500 MelScheinerone Placebo labeled as MelScheinerone 50 % Mortality on MelScheinerone 2500 Placebo MelScheineron labeled as placebo 25% Mortality on Placebo 10
11 The Unfortunate Saga of MelScheinerone 5000 patients at high risk of CV death 2500 MelScheinerone Placebo labeled as MelScheinerone 50 % Mortality on MelScheinerone 2500 Placebo MelScheineron labeled as placebo 25% Mortality on Placebo AFFIRM Trial: Percent of patients Crossing-Over Percent of patients crossing over (%) AFFIRM Investigators. NEJM 2002;347:
12 AFFIRM Trial: Percent of Patients in NSR Percent of patients in NSR (%) Only 28% contributing meaningful data AFFIRM Investigators. NEJM 2002;347: Atrial Fibrillation Follow-Up Investigation of Rhythm Management A subsequent on treatment statistical analysis gives a very different interpretation of the AFFIRM Trial results 12
13 Atrial Fibrillation Follow-Up Investigation of Rhythm Management Due to the large number of cross-overs, the poor efficacy of AADs with many rhythm control patients in AF and the fact that many rate control patients were actually in NSR, Intention to treat analysis may be misleading A subsequent on treatment statistical analysis gives a very different interpretation of the AFFIRM Trial results AFFIRM Trial: Importance of NSR (Circ 2004; 109: ) 13
14 AFFIRM Trial: Importance of NSR (Circ 2004; 109: ) AFFIRM Trial: Importance of NSR (Circ 2004; 109: ) 14
15 AFFIRM Trial: Importance of NSR (Circ 2004; 109: ) Danish Investigators of Arrhythmia and Mortality on Dofetitlde in CHF (DIAMOND- CHF) (NEJM 1999;341: ) 1518 patients with symptomatic CHF and LV dysfunction Double-blind, placebo controlled at 34 Danish centers Inclusion criteria hospitalized patients with new or worsening CHF and at least one episode of SOB on minimal exertion or at rest or PND ECHO with wall motion score of 1.2 or less (EF approx. 35%) Exclusion criteria acute MI within 7 days K + < 3.6 or > 5.5 heart rate < 50 creatinine clearance < 20 cc/min SA or AV block without a pacer recent Class I or III antiarrhythmics history of proarrhythmia planned or recent PTCA/CABG QTc >460msec (>500 if bundle branch block) Aortic stenosis BP > 115 diastolic or < 80 systolic ICD 15
16 Dofetilide in patients with CHF and LV dysfunction (DIAMOND-CHF) (NEJM 1999;341: ) DIAMOND-CHF Sub study of patients in AF at time of enrollment (Pedersen et. al. Circ 2001;104: ) Probability of survival during treatment and follow-up periods in 506 patients with LV dysfunction and AF-AFl at baseline treated with dofetilide or placebo. 16
17 DIAMOND-CHF Sub study of patients in AF at time of enrollment (Pedersen et. al. Circ 2001;104: ) Survival rates of patients treated with or placebo who converted or did not convert to SR. Antiarrhythmic Drugs Cause a lot of side effects Most do not work very well for patients with atrial fibrillation Many cannot be given to patients with poor LV function, CAD, sick sinus etc. All have black box warnings from the FDA which are scary to patients 17
18 Rhythm Control for AF: Antiarrhythmic Drugs Treatment Choices (oral) Class 1A Class 1C Class 3 Flecainide Propafenone Atrial Fibrillation: Prevention of Recurrence after Cardioversion by Quinidine Percent of patients in NSR (%) Coplen SE. Circulation. 1990;82: Time (months) 18
19 Odds Ratio for Total Mortality for Patients Treated with Quinidine Compared to Control RCT n Boissel 212 Byrne-Quinn 92 Hartel 175 Hillestad 100 Lloyd Sodermark ALL STUDIES N = Quinidine Better Coplen SE. Circulation. 1990;82: Quinidine Worse Odds Ratio (Quinidine: Control) Maintenance of Sinus Rhythm with Oral Sotalol in Patients with Symptomatic Atrial Fib / Flutter (Benditt et al AJC 1999;84: ) 253 patients with atrial fibrillation / flutter Multicenter, randomized, double-blind study Evaluated safety and efficacy of 3 fixed doses of d,lsololol (80, 120 or 160 mg bid) Primary endpoint: time to recurrence of AF Treatment continued 1 year or until AF recurred Transtelephonic monitoring used 19
20 Time to documented AF on Sotalol (80, 120, 160 mg bid) or placeb0 Intention to Treat 45%" 40%" 30%" 28%" Sotalol Side Effects Compared to Placebo (Benditt et al AJC 1999;84: ) 20
21 21
22 Dronedarone: Amiodarone Without Side Effects or Just a Different Poison? EURIDIS AND ADONIS (Singh B et al. N Engl J Med 2007;357: ) Age >21 years One episode of Afib in prior 3 months In NSR for one hour before randomization Randomized 2:1 Dronedarone 400mg bid or placebo Endpoint: Time to first documented AF lasting 10 minutes Secondary endpoints Symptoms related to AF Mean Ventricular Rate during first AF recurrence 22
23 EURIDIS and ADONIS Primary Endpoint: Median # Days to First AF Recurrence (Singh et al NEJM 2007;357:987-99) Kaplan-Meier Incidence of First Recurrence of A Fib or Flutter (Singh et al NEJM 2007;357:987-99) 23
24 ANDROMEDA Antiarrhythmic Trial with Dronedarone in Moderate-to-Severe CHF Evaluating Morbidity Decrease Stopped by DSMB January,2003 after 627 patients enrolled due to increased mortality in Dronedarone group PALLUS Trial Age > 65 years with at least one of the following major risk factors systemic arterial embolism myocardial infarction documented coronary artery disease prior stroke symptomatic heart failure Age > 75 years + hypertension and diabetes mellitus. Exclusions: NYHA Class IV or unstable Class III CHF Endpoints Major cardiovascular events (stroke, systemic arterial embolism, myocardial infarction or cardiovascular death) Cardiovascular hospitalization or death from any cause 10,800 patients enrolled in 43 countries at 700 sites Randomized to dronederone 400 mg bid or placebo 24
25 PALLUS Trial Adverse event CV death, MI, stroke, systemic embolism Death, unplanned CV hospitalization* Placebo n=1577 n (%) Dronedarone n=1572, n (%) Hazard ratio 14 (0.9) 32 (2) (5.1) 118 (7.5) Death 7 (0.4) 16 (1) MI 3 (0.2) 3 (0.2) Stroke 7 (0.4) 17 (1.1) HF hospitalization 15 (1) 34 (2.2) p Antiarrhythmic Drugs for Maintaining Sinus Rhythm After Cardioversion of Atrial Fibrillation: A Systematic Review of Randomized Controlled Trials Arch Intern Med. 2006;166: trials were included, with a total of 11,322 pts All drugs increased withdrawals due to adverse effects (NNH, 9-27) All but amiodarone and propafenone increased proarrhythmia (NNH, ) Class IA drugs (disopyramide, quinidine), pooled, were associated with increased mortality compared with controls P =.04; NNH, 109 No other antiarrhythmic showed a significant effect on mortality compared with controls 25
26 Withdrawals and Proarrhythmia Lafuente-Lafuente, C. et al. Arch Intern Med 2006;166: Overall Mortality Lafuente-Lafuente, C. et al. Arch Intern Med 2006;166:
27 Death by Treadmill! 59 year old recently retired lawyer No cardiac or non-cardiac diseases Spring 2007 first Afib while visiting NYC Hospitalized 4 days, spontaneous conversion, echo normal and DC on warfarin and metoprolol California cardiologist changed to ASA Afib got worse, occurring anytime Treated with propafenone but had side effects Flecainide started 100 mg bid, increased to 150 mg bid, still had Afib October, 2007 was at movie and felt lightheaded Went to urgent care where sinus rate in 30s and metoprolol decrease to 25 mg a day Referred for a treadmill 27
28 11/2/11 TM (November 2, 2007) Baseline TM EKG #1 28
29 11/2/11 TM EKG #2 TM EKG #3 Collapse and was unconscious for 15 seconds 29
30 Saw Dr. Winkle on November 15, 2007 Patient declined further antiarrhythmic drugs Metoprolol 25 mg a day (very fatigued on higher doses changed to diltiazem with gradual dose escalation to 240 mg AM and 120 mg PM Still with several episodes of Afib a week lasting for hours at a time during which he could not do much Underwent successful Afib ablation March 21, AF free ever since. Ablation to treat AF: Frequent Negative Comments It takes all day to do It does not work Repeat ablations do not work There are too many complications It works, but almost all patients eventually have a recurrence Most patients still have to stay on anticoagulation even if they are not having AF None of these are true in
31 Sequoia Hospital AF Ablation Results 1504 AF ablations in 1125 patients as of Dec, 31, 2010 All patients symptomatic and most have failed rate control and rhythm control Includes both paroxysmal and persistent AF with and without heart disease 270 (30.9%) AF1 (paroxysmal) 423 (52.8%) AF2 (persistent) 150 (16.3%) AF3 (long-standing persistent) Sequoia Hospital AF Ablation Results Success = no AF off of all drugs Partial success = no AF on AAD Most partial successes and failures offered redo ablation Failure = AF on AAD 3 months after final procedure Both Single Procedure Success rates and final status reported 31
32 AF Ablation Outcome by AF Type (No AF off of drugs) (Winkle et. al. Am Heart J 2011;162: ) Sequoia Hospital: Reasons Why Patients do not have a Redo Ablation Reason for no Redo Redo done or to be done a`er Dec (Last date of panent enrollment) Total Females Males N = 138 N = 49 N (39.9%) 12 (24.5%) 43 (48.3%) Physician or Medical Decision Extensive LA scar AV node ablanon Medical condinons Death/Terminal cancer Prior MAZE or AF ablanon elsewhere Total Physician or Medical Decision 31(22.5%) 9 (18.4%) 22 (24.7%) PaNent Decision Much improved a`er ablanon 7 5 (10.2%) 2 (2.3%) No AF on drugs a`er ininal ablanon (22.4%) 12 (13.5%) PaNent preference (24.5%) 10 (11.2%) Total PaNent Decision 52 (37.7%) 29 (57.1%)* 25 (27.0%)* *P = Females vs. Males 32
33 Freedom from AF at 1,3 and 5 years for those patients Going all the Way 1 year AF free rate 3 year AF free rate 5 year AF free rate Paroxysmal AF1 94.5% 94.5% 94.5% Persistent AF2 87.9% 82.9% 77.3% Long-standing AF3 83% 79.4% 74.4% Long term outcome to almost 7 years for patients cured by the first ablation or who come back for a redo if the first ablation fails 33
34 How to do a faster and safer AF ablation Use only one groin Do only one transseptal puncture (you can put 2 catheters thru the single stick) Use an RF needle for the transseptal No Foley catheter Have dedicated echo machine in EP lab Use general anesthesia Use the open irrigated tip catheter at 50W Mark the location of the esophagus Keep the ACT at 225 and infuse heparin thru the transseptal sheath Reverse heparin and pull sheaths in the EP lab Avoid gadgets : Stereotaxis, Cyroballoons, Robots Zero Gravity: A cheaper way to reduce operator radiation than $2M magnets! 34
35 Comparison of Cryoballoon to RF ablation Cryoballoon Medronic FDA data (n = 163 patients) Radiofrequency at Sequoia Hospital (n = >1800 ablations) Superior outcome Cryo or RF Death 0.6% 0.0% RF Superior Stroke/TIA 4.3% 0.26% RF Superior Heart Attack 1.2% 0.0% RF Superior Pulmonary Vein Stenosis 3.1% 0.07% RF Superior Bleeding Needing Transfusion AV fistula/ Pseudoaneurysms 1.8% 0.13% RF Superior 1.8% 0.93% RF Superior Phrenic Nerve Paralysis 16% 0.0% RF Superior Procedure Time 6 hours 11 minutes 2 hours RF Superior Flouroscopy Time 62.8 minutes 60.2 minutes RF Superior 1Year Cure Rate 69.9% 86.2% RF Superior With OITC Ablate at 50W and Keep the Catheter Moving (Winkle et. al. PACE 2011;34 : ) 35
36 ATRIAL FIBRILLATION ABLATION: PERPETUAL MOTION OF OPEN IRRIGATED TIP CATHETERS AT 50 WATTS IS SAFE AND IMPROVES OUTCOMES (Winkle et. al. PACE 2011;34 : ) Kaplan-Meier Freedom from Afib after initial ablation (n = 843) AF1 = 32% AF2 = 50.2% AF3 = 17.8% Sequoia Hospital Afib Ablations Procedure Times by Catheter and Power (N = 1122) *P<0.041 P< *P<0.001 *P<0.001 * Compared to CTC 36
37 The use of the RF needle for transseptal punctures (Winkle et. al. Heart Rhythm 2011;8: ) Baylis NRG RF Transseptal Needle 37
38 Fewer Complications and better Septal Crossing with the RF Needle (Sequoia Hospital: 1495 AF Ablations) With OITC: Lower Target ACT to 225 Seconds and Reduce Complications (Winkle et. al. AJC 2011;107: ) 38
39 Safety of Lower Activated Clotting Times During Afib Ablation using Open Irrigated Tip Catheters and a Single Transseptal Puncture (Winkle et. al. AJC 2011;107: ) ) Sequoia Hospital AF Ablation Trends over Time (1504 AF ablations in 1125 patients) 39
40 Sequoia Hospital AF Ablation: all Major Complications from in 1504 Ablations Sequoia Hospital AF Ablation Trends over Time (1504 AF ablations in 1125 patients) 40
41 Why Patients Should Skip AADs and Go Directly to Ablation The risk of permanent side effect from ablation is about 1:400 which is the risk of stroke every 2-3 months for the lowest risk AF groups Every drug a patient fails lowers their chance of a successful ablation Every randomized trial of Ablation vs. AAD strongly favors Ablation Sequoia Hospital AF Ablation: Impact of number of AADs failed pre-ablation (Europace in press) 942 patients with paroxysmal AF (n = 348) and persistent AF (n = 594) We examined the impact of number of AADs failed on clinical characteristics and ablation outcomes 41
42 Sequoia Hospital AF Ablation: Change in clinical parameters as patients fail more AADs Number of Drugs Failed No Drugs (n = 195) One Drug (n = 400) Two Drugs (n = 232) 3 or MoreDrugs (n = 115) P Value Le` atrial size (cm) Age (years) * DuraNon of AF (years) * Repeat ablanons 26. 2% 26.8% 31.9% 35.7% 0.045* % Female 27.7% 30.0% 30.1% 40.9% 0.037* Average CHADS 2 score Hypertension 45.6% 47.2% 46.6% 47.8% Diabetes 7.7% 8.5% 10.3% 6.1% Coronary artery disease 11.3% 13.0% 15.5% 16.5% Dilated cardiomyopathy 7.7% 8.5% 10.3% 6.1% Body Mass Index AF1 (paroxysmal AF) 43.1% 64.2% 35.0% 34.7% 0.003* Prior Stroke/TIA 7.2% 5.3% 7.3% 9.6% *StaNsitcally significant, AbbreviaNons: AF = atrial fibrillanon, TIA = transient ischemic agack Sequoia Hospital AF Ablation: Reasons why some patients did not fail AAD before ablation Reason for no prior annarrhythmic drug Total (N = 195) Physician or Medical Decision Sinus node disease/bradycardia 25 ConducNon system disease 1 Coronary artery disease 6 Cardiomyopathy 6 Unexpained syncope 1 Liver or kidney disease 3 Total Physician or Medical Decision 42(21.5%) PaNent Decision PaNent preference 153 Total PaNent Decision 153 (78.5%) 42
43 Sequoia Hospital: AF Ablation Outcome after Initial and Final Ablation by Number of AADs failed Pre-Ablation (Europace in press) Sequoia Hospital AF Ablation: Multivariate analysis of factors predicting failure of initial and final ablations AF recurrence after Initial Ablation AF recurrence after Final Ablation Variable Hazard ratio Hazard ratio 95% CI P Value Hazard ratio Hazard ratio 95% CI P Value Age * Left Atrial size * * BMI (Body Mass Index) Atrial Fibrillation Duration Gender (female vs. male) * * AF type (paroxysmal vs. persistent) * * CAD (absent vs. present) Hypertension (absent vs.present) Diabetes (absent vs. present) Total # of antiarrhythmics failed * * * Statistically Significant, abbreviations: AF = atrial fibrillation, CAD = coronary artery disease, CI = confidence interval 43
44 Summary of Randomized AF Ablation Trials vs. Drugs * Excluding RAAFT ThermoCool AF Trial (Wilber et. Al. JAMA 2010;303(4): ) 44
45 ThermoCool AF Trial (Wilber et. Al. JAMA 2010;303(4): ) Kaplan-Meier Curves of Time to Protocol-Defined Treatment Failure, Recurrence of Symptomatic Atrial Arrhythmia, and Recurrence of Any Atrial Arrhythmia by Treatment Group RF Ablation vs. Antiarrhythmic Drugs as First-Line Treatment of Sx Atrial Fibrillation: A Randomized Trial (Wazni et al. JAMA 2005; 293: ) 45
46 RF Ablation vs. Antiarrhythmic Drugs as First-Line Treatment of Sx Atrial Fibrillation: A Randomized Trial (Wazni et al. JAMA 2005; 293: ) RF Ablation vs. Antiarrhythmic Drugs as First-Line Treatment of Sx Atrial Fibrillation: A Randomized Trial (Wazni et al. JAMA 2005; 293: ) Quality of Life Assessment*. 46
47 2010 European Guidelines:Treatment Recomendations Conclusions Rate control is a poor solution for AF as it only sweeps the dirt under the carpet AADs do not work in a majority of patients and cause a lot of side effects and possibly deaths Ablation can be done safely, in a reasonable amount of time and can restore NSR in a high percentage of patients In randomized trials ablation is vastly superior to AADs The earlier in the AF course ablation is done the greater the chance of eliminating AF The time has come for ablation to be considered as first line treatment for most patients with AF 47
48 Dr. Moss Thank you for all you have done over so many years to help our patients live longer and better quality lives! 48
Half Moon Bay Treatment of Atrial Fibrillation. Dr. Roger A. Winkle MD. Silicon Valley Cardiology, PAMF, Sutter Health Sequoia Hospital
Half Moon Bay 2018 Treatment of Atrial Fibrillation Dr. Roger A. Winkle MD Silicon Valley Cardiology, PAMF, Sutter Health Sequoia Hospital Disclosures: Investor Farapulse Things a Primary Care Doctor Should
More informationATRIAL FIBRILLATION: REVISITING CONTROVERSIES IN AN ERA OF INNOVATION
ATRIAL FIBRILLATION: REVISITING CONTROVERSIES IN AN ERA OF INNOVATION Frederick Schaller, DO, MACOI,FACP Adjunct Clinical Professor Touro University Nevada DISCLOSURES I have no financial relationships
More informationAtrial Fibrillation 2009
Atrial Fibrillation 2009 Michael Glikson, MD Director of Pacing & Electrophysiology Leviev Heart Center Sheba medical Center Sheba Medical Center Tel Hashomer The Leviev Heart Center Rhythm vs rate control
More informationBasics of Atrial Fibrillation. By Mini Thannikal NP-BC Mount Sinai St Luke s Hospital New York, NY
Basics of Atrial Fibrillation By Mini Thannikal NP-BC Mount Sinai St Luke s Hospital New York, NY Atrial Fibrillation(AF) is a supraventricular tachyarrhythmia characterized by uncoordinated atrial activation
More informationJay Simonson, MD, FACC, FHRS Medical Director, Cardiac Electrophysiology Park Nicollet Heart and Vascular Center
Jay Simonson, MD, FACC, FHRS Medical Director, Cardiac Electrophysiology Park Nicollet Heart and Vascular Center A-Fib Facts Yes, you may be able to blame your parents It is more of a nuisance than a
More informationSupplementary Online Content
Supplementary Online Content Morillo CA, Verma A, Connolly SJ, et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line Treatment of Paroxysmal Atrial Fibrillation (RAAFT-2): a randomzied clinical
More informationAtrial Fibrillation Etiologies and Treatment. Shawn Liu Learner Centered Learning Goal
Atrial Fibrillation Etiologies and Treatment Shawn Liu Learner Centered Learning Goal Pathophysiology Defined by the absence of coordinated atrial systole Results from multiple reentrant electrical waves
More informationAtrial Fibrillation Ablation Recent Clinical Trials That Changed (or not) My Practice
Atrial Fibrillation Ablation Recent Clinical Trials That Changed (or not) My Practice Walid Saliba, MD, FHRS Director, Atrial Fibrillation Center Director EP laboratory Heart and Vascular Institute Cleveland
More informationRate and Rhythm Control of Atrial Fibrillation
Rate and Rhythm Control of Atrial Fibrillation April 21, 2017 춘계심혈관통합학술대회 Jaemin Shim, MD, PhD Arrhythmia Center Korea University Anam Hospital Treatment of AF Goal Reducing symptoms Preventing complication
More informationAtrial Fibrillation: Rate vs. Rhythm. Michael Curley, MD Cardiac Electrophysiology
Atrial Fibrillation: Rate vs. Rhythm Michael Curley, MD Cardiac Electrophysiology I have no relevant financial disclosures pertaining to this topic. A Fib Epidemiology #1 Most common heart rhythm disturbance
More informationSaudi Heart Association February 22, 2011
Pharmacological Therapy of Atrial Fibrillation: Recent Advances Dr Martin Green Professor of Medicine (Cardiology) University of Ottawa Saudi Heart Association February 22, 2011 Atrial Fibrillation Drugs
More informationAblation Should Not Be Used as Primary Therapy for Treatment of Patients with Atrial Fibrillation
Ablation Should Not Be Used as Primary Therapy for Treatment of Patients with Atrial Fibrillation 25 October 2008 Update in Electrocardiography and Arrhythmias Zian H. Tseng, M.D., M.A.S. Assistant Professor
More informationABLATION OF CHRONIC AF
ABLATION OF CHRONIC AF A PISAPIA ST JOSEPH HOSPITAL MARSEILLE MEET 2008 Atrial Fibrillation The most common significant heart rhythm disturbance Incidence increases with age and the development of structural
More informationAre Drugs Better? Dr Mauro Lencioni. Drugs or ablation as first line treatment for AF? Consultant Cardiologist & Electrophysiologist
Are Drugs Better? Drugs or ablation as first line treatment for AF? Dr Mauro Lencioni Consultant Cardiologist & Electrophysiologist The Philosophical Issue What do we mean by Better? Outcome measures Measurement
More informationLong-Term Outcome and Risks of Catheter Ablation for Atrial Fibrillation
Long-Term Outcome and Risks of Catheter Ablation for Atrial Fibrillation Carlo Pappone, MD, PhD, FACC EP Director, Villa Maria Hospital Group How many times AF can increase mortality DO MORTALITY REALLY
More information5/5/2010. World incidence 720, 000 new cases / year. World prevalence 5.55 million AF prevalence increasing with aging of population
Atrial Fibrillation: Guidelines through clinical cases and 2010 updates Samy Claude ELAYI Cardiac Clinical Pacing and Electrophysiology UK World incidence 720, 000 new cases / year World prevalence 5.55
More informationCatheter Ablation for Atrial Fibrillation: Patient Selection and Outcomes
Catheter Ablation for Atrial Fibrillation: Patient Selection and Outcomes Francis Marchlinski, MD Richard T and Angela Clark President s Distinguished Professor Director Cardiac Electrophysiolgy University
More informationTreatment of Atrial Fibrillation in Heart Failure
Stockholm, September 1st 2010 Treatment of Atrial Fibrillation in Heart Failure Rhythm control: Which drugs? Stefan H. Hohnloser J.W. Goethe University Frankfurt, Germany Presenter disclosure information:
More informationPolypharmacy - arrhythmic risks in patients with heart failure
Influencing sudden cardiac death by pharmacotherapy Polypharmacy - arrhythmic risks in patients with heart failure Professor Dan Atar Head, Dept. of Cardiology Oslo University Hospital Ullevål Norway 27.8.2012
More informationAF and arrhythmia management. Dr Rhys Beynon Consultant Cardiologist and Electrophysiologist University Hospital of North Staffordshire
AF and arrhythmia management Dr Rhys Beynon Consultant Cardiologist and Electrophysiologist University Hospital of North Staffordshire Atrial fibrillation Paroxysmal AF recurrent AF (>2 episodes) that
More informationAtrial Fibrillation: Guidelines through clinical cases and 2010 updates
Atrial Fibrillation: Guidelines through clinical cases and 2010 updates Samy Claude ELAYI Cardiac Clinical Pacing and Electrophysiology World incidence 720, 000 new cases / year World prevalence 5.5 million
More informationΚΑΤΑΛΥΣΗ ΚΟΛΠΙΚΗΣ ΜΑΡΜΑΡΥΓΗΣ. ΥΠΕΡ. Michalis Efremidis MD Second Department of Cardiology Evangelismos General Hospital
ΚΑΤΑΛΥΣΗ ΚΟΛΠΙΚΗΣ ΜΑΡΜΑΡΥΓΗΣ. ΥΠΕΡ. Michalis Efremidis MD Second Department of Cardiology Evangelismos General Hospital Rate control versus Rhythm control for Atrial Fibrillation AFFIRM N Engl J Med 2002;347:1825-33
More informationAF Today: W. For the majority of patients with atrial. are the Options? Chris Case
AF Today: W hat are the Options? Management strategies for patients with atrial fibrillation should depend on the individual patient. Treatment with medications seems adequate for most patients with atrial
More informationGeriatric Grand Rounds
Geriatric Grand Rounds Tuesday, April 13, 21 12: noon Dr. Bill Black Auditorium Glenrose Rehabilitation Hospital In keeping with Glenrose Rehabilitation Hospital policy, speakers participating in this
More informationDebate PRO. Dronedarone is an important drug in the management of paroxysmal atrial fibrillation. John Camm
ESC ICM - Internationales Congress Center München 2012 Atrial Fibrillation Controversies in Medical Treatment Debate Dronedarone is an important drug in the management of paroxysmal atrial fibrillation
More informationESC Stockholm Arrhythmias & pacing
ESC Stockholm 2010 Take Home Messages for Practitioners Arrhythmias & pacing Prof. Panos E. Vardas Professor of Cardiology Heraklion University Hospital Crete, Greece Disclosures Small teaching fees from
More informationInnovations in AF Management
Innovations in AF Management Barry Boilson MD PhD FRCPI boilson.barry@mayo.edu Disclosures Relevant None financial relationship(s) with industry None Off Label Usage None Overview Mechanisms of AF AF as
More informationCatheter Ablation for AF: Patients, Procedures, Outcomes
Catheter Ablation for AF: Patients, Procedures, Outcomes John Sapp Director Heart Rhythm, QEII Health Sciences Centre Professor of Medicine, Dalhousie University Atrial Fibrillation Atrial Fibrillation
More informationRebuttal. Jerónimo Farré MD 2010
Rebuttal 1.We do not know what are the types of AF in which ablation is worthless or most effective 2.Waiting implies to consider the ablation at an older age and when the duration of the history of AF
More informationWhat s New in the AF Guidelines
Impact on New AF Guidelines on Heart Failure Management Gothenburg - May 22 nd 2011 Europace (2010) 12, 1360-420 http://europace.oxfordjournals.org JACC (2011) 57, 223-42 http://www.cardiosource.org What
More informationDronedarone: Need to Perform a CV Outcome Safety Study
Dronedarone: Need to Perform a CV Outcome Safety Study Gerald V. Naccarelli M.D. Consultant: Glaxo-Smith-Kline, Pfizer, Sanofi, Boehringer-Ingelheim, Daiichi-Sankyo, Bristol Myers Squibb, Otsuka, Janssen
More information3/25/2017. Program Outline. Classification of Atrial Fibrillation
Alternate Strategies to Antiarrhythmic Therapy: The Role of Ablation Jennifer El Aile, MS, AGPCNP-BC Electrophysiology Nurse Practitioner Clinical Lecturer at the University of Michigan Program Outline
More informationArrhythmias and Heart Failure Dr Chris Lang Consultant Cardiologist and Electrophysiologist Royal Infirmary of Edinburgh
Arrhythmias and Heart Failure Dr Chris Lang Consultant Cardiologist and Electrophysiologist Royal Infirmary of Edinburgh Arrhythmias and Heart Failure Ventricular Supraventricular VT/VF Primary prevention
More informationWhat s new in my specialty?
What s new in my specialty? Jon Melman, MD Heart Rhythm Specialists McKay-Dee Hospital some would say some would say my specialty 1 some would say my specialty First pacemaker 1958 some would say my specialty
More informationCost and Prevalence of A fib. Atrial Fibrillation: Guideline Directed Treatment. Prevalence of A Fib. Risk Factors for A Fib. Risk Factors for A Fib
Atrial Fibrillation: Guideline Directed Treatment Melissa Wendell, FNP-C, MSN Heart Failure - Lead Nurse Practitioner, Aspirus Wausau Hospital and Aspirus Cardiology Cost and Prevalence of A fib 33.5 million
More informationAtrial fibrillation and advanced age
Atrial fibrillation and advanced age Prof. Fiorenzo Gaita Director of the Cardiology School University of Turin, Italy Prevalence of AF in the general population Prevalence and age distribution in patients
More informationStuart Beldner, MD, FHRS Assistant Professor NSLIJ Hofstra School of Med
Stuart Beldner, MD, FHRS Assistant Professor NSLIJ Hofstra School of Med None There s no reason to panic. While it is true that one of the crew members is ill, slightly. Absence of discrete P waves Chaotic
More informationRate Control versus Rhythm Control in NSTEMI
Rate Control versus Rhythm Control in NSTEMI Gulmira Kudaiberdieva, MD, FESC Adana, Turkey Conflict of interest: None to declare Istanbul - 2012 OUTLINE Significance of AF in ACS Prognostic value of AF
More informationFibs and Flutters: The Heart of the Matter
Fibs and Flutters: The Heart of the Matter Anita Ralstin, CNP By the Numbers Atrial Fibrillation Hospital Discharges /quarter for 2012 -- 116,500 Average Length of Stay 4 days Projected that 20% of those
More informationAtrial Fibrillation and Heart Failure: Rate vs. Rhythm Control Time for Re-evaluation
Atrial Fibrillation and Heart Failure: Rate vs. Rhythm Control Time for Re-evaluation ANIL K. BHANDARI, M.D, Director, Electrophysiology and EPS Fellowship Program Good Samaritan Hospital/ Harbor UCLA
More informationInvasive and Medical Treatments for Atrial Fibrillation. Thomas J Dresing, MD Section of Electrophysiology and Pacing Cleveland Clinic
Invasive and Medical Treatments for Thomas J Dresing, MD Section of Electrophysiology and Pacing Cleveland Clinic Disclosures Fellow s advisory panel for St Jude Medical Speaking honoraria from: Boston
More informationAtrial Fibrillation Ablation in Patients with Heart Failure
Atrial Fibrillation Ablation in Patients with Heart Failure Eleftherios M. Kallergis, MD, PhD, FESC Cardiology Department, Heraklion University Hospital Since auricular fibrillation so often complicates
More informationRhythm Control: Is There a Role for the PCP? Blake Norris, MD, FACC BHHI Primary Care Symposium February 28, 2014
Rhythm Control: Is There a Role for the PCP? Blake Norris, MD, FACC BHHI Primary Care Symposium February 28, 2014 Financial disclosures Consultant Medtronic 3 reasons to evaluate and treat arrhythmias
More information» A new drug s trial
» A new drug s trial A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause
More informationAtrial Fibrillation Ablation in Patients with Heart Failure
Atrial Fibrillation Ablation in Patients with Heart Failure Eleftherios M. Kallergis, MD, PhD, FESC Cardiology Department, Heraklion University Hospital Since auricular fibrillation so often complicates
More informationAtrial Fibrillation New Approaches, Techniques, and Technology
New Cardiovascular Horizons 2015 May 28, 2015 New Orleans, Louisiana Atrial Fibrillation New Approaches, Techniques, and Technology State of the Art - - 2015 Richard Abben, M D Director, Cardiac Arrhythmia
More informationControversies in Atrial Fibrillation and HF
Controversies in Atrial Fibrillation and HF Dr.Yahya Al Hebaishi Cardiac electrophysiology division, PSCC, Riyadh Atrial Fibrillation: Rate or Rhythm? HF and AF: the twin epidemic of cardiovascular disease.
More informationDipen Shah Cardiology Service, University Hospitals, Geneva Switzerland
Dipen Shah Cardiology Service, University Hospitals, Geneva Switzerland Disclosures Research Grants: Biosense Webster, St. Jude, Bard, Endosense, Biotronik Speakers Honoraria: Biosense Webster, Endosense,
More informationAblation Update and Case Studies. Lawrence Nair, MD, FACC Director of Electrophysiology Presbyterian Heart Group
Ablation Update and Case Studies Lawrence Nair, MD, FACC Director of Electrophysiology Presbyterian Heart Group Disclosures No financial relationships to disclose Objectives At the conclusion of this activity,
More informationManagement of ATRIAL FIBRILLATION. in general practice. 22 BPJ Issue 39
Management of ATRIAL FIBRILLATION in general practice 22 BPJ Issue 39 What is atrial fibrillation? Atrial fibrillation (AF) is the most common cardiac arrhythmia encountered in primary care. It is often
More informationAtrial Fibrillation and the NOAC s. John Raymond MS, PA-C, MHP February 10, 2018
Atrial Fibrillation and the NOAC s John Raymond MS, PA-C, MHP February 10, 2018 Pathogenesis EPIDEMIOLOGY Arrhythmia-related hospitalisations in the US Ventricular fibrillation 2% Atrial fibrillation 34%
More informationHow does the heart work? The heart is muscle whose main function is a pump; to push blood the rest of your body.
1 You have a condition called atrial fibrillation. I would like you to learn more about this condition. You should read about it below, and can also watch an Internet program about it. After reading about
More informationUpdate in the Management of Atrial Fibrillation
Update in the Management of Atrial Fibrillation Gregory M Marcus, MD, MAS Associate Professor of Medicine Division of Cardiology University of California, San Francisco Disclosures Research: Gilead, Medtronic,
More informationDysrhythmias 11/7/2017. Disclosures. 3 reasons to evaluate and treat dysrhythmias. None. Eliminate symptoms and improve hemodynamics
Dysrhythmias CYDNEY STEWART MD, FACC NOVEMBER 3, 2017 Disclosures None 3 reasons to evaluate and treat dysrhythmias Eliminate symptoms and improve hemodynamics Prevent imminent death/hemodynamic compromise
More informationDevices and Other Non- Pharmacologic Therapy in CHF. Angel R. Leon, MD FACC Division of Cardiology Emory University School of Medicine
Devices and Other Non- Pharmacologic Therapy in CHF Angel R. Leon, MD FACC Division of Cardiology Emory University School of Medicine Disclosure None University of Miami vs. OSU Renegade Miami football
More informationAF#in#pa(ents#with#CAD# Is#dronedarone#a#good#choice?!
AF#in#pa(ents#with#CAD# Is#dronedarone#a#good#choice?! DRUG#PROPHYLAXIS#OF#AF:# FOCUS#ON#DRONEDARONE# Friday#16C10C2015# Harry%JGM%Crijns% Maastricht,%The%Netherlands% Disclosures Harry Crijns - research
More information2015 Atrial Fibrillation Therapy Meds, Shock, or Ablate? D. Scott Kirby MD, FACC Cardiac Electrophysiologist
2015 Atrial Fibrillation Therapy Meds, Shock, or Ablate? D. Scott Kirby MD, FACC Cardiac Electrophysiologist Todays Objectives Atrial Fibrillation evaluation and treatment from an EP perspective Multimodal
More informationUnderstanding Atrial Fibrillation Management. Roy Lin, MD
Understanding Atrial Fibrillation Management Roy Lin, MD Disclosure None Definition of atrial fibrillation Atrial fibrillation is a supraventricular tachyarrhythmia characterized by uncoordinated atrial
More informationAF :RHYTHM CONTROL BY DR-MOHAMMED SALAH ASSISSTANT LECTURER CARDIOLOGY DEPARTMENT
AF :RHYTHM CONTROL BY DR-MOHAMMED SALAH ASSISSTANT LECTURER CARDIOLOGY DEPARTMENT 5-2014 Atrial Fibrillation therapeutic Approach Rhythm Control Thromboembolism Prevention: Recommendations Direct-Current
More informationAtrial Fibrillation and Heart Failure: A Cause or a Consequence
Atrial Fibrillation and Heart Failure: A Cause or a Consequence Rajat Deo, MD, MTR Assistant Professor of Medicine Division of Cardiology, Electrophysiology Section University of Pennsylvania November
More informationSamer Nasr, M.D. Mount Lebanon Hospital.
Samer Nasr, M.D. Mount Lebanon Hospital. Lone atrial fibrillation: Younger than 60 years old. No clinical or echo evidence of cardiopulmonary disease. Favorable prognosis. Thromboembolism usually not
More informationCurrent Guideline for AF Treatment. Young Keun On, MD, PhD, FHRS Samsung Medical Center Sungkyunkwan University School of Medicine
Current Guideline for AF Treatment Young Keun On, MD, PhD, FHRS Samsung Medical Center Sungkyunkwan University School of Medicine Case 1 59 year-old lady Sudden palpitation and breathlessness for 12 hours
More informationAntiarrhythmic Drugs and Ablation in Patients with ICD and Shocks
Antiarrhythmic Drugs and Ablation in Patients with ICD and Shocks Alireza Ghorbani Sharif, MD Interventional Electrophysiologist Tehran Arrhythmia Clinic January 2016 Recurrent ICD shocks are associated
More informationRate or Rhythm Control? Epidemiology. Relevant Advances in Atrial Fibrillation 6/20/2011. Stroke Prophylaxis
Relevant Advances in Atrial Fibrillation Stroke Prophylaxis Managing Atrial Fibrillation: Tips for the Generalist Antiarrhythmic Drug Therapy Ablation Gregory M Marcus, MD, MAS Assistant Professor of Medicine
More informationCatheter Ablation for Treatment of Atrial Fibrillation 2010 and Beyond
Catheter Ablation for Treatment of Atrial Fibrillation 2010 and Beyond John M. Miller, MD Professor of Medicine Indiana University School of Medicine Director, Clinical Cardiac Electrophysiology Krannert
More informationDr Chris Ellis. Consultant Cardiologist Auckland City Hospital Auckland
Dr Chris Ellis Consultant Cardiologist Auckland City Hospital Auckland 8:30-9:25 WS #189: Anticoagulation in AF 9:35-10:30 WS #201: Anticoagulation in AF (Repeated) Anticoagulation in Atrial Fibrillation
More informationPLEASE TAKE A MOMENT TO COMPLETE THE PRE-TEST
PLEASE TAKE A MOMENT TO COMPLETE THE PRE-TEST Atrial Fibrillation Affects 2 to 5 million US patients 1% of population Associated with older age and chronic heart disease, especially HF Comorbidities AF
More informationAtrial Fibrillation and Common Supraventricular Tachycardias. Sunil Kapur MD
Atrial Fibrillation and Common Supraventricular Tachycardias Sunil Kapur MD Cardiac Electrophysiology Brigham and Women s Hospital Instructor, Harvard Medical School No disclosures Cardiac Conduction:
More informationEtienne Aliot. University of Nancy - France
Etienne Aliot University of Nancy - France Disclosures Consulting fees : - Bayer, Boehringer Ingelheim,GSK, MedaPharma, Pfizer/BMS,Sanofi Aventis. - Biotronik,Medtronic,St Jude Medical. Electrical vs Pharmacological
More informationUse of Antiarrhythmic Drugs for AF Who, What and How? Dr. Marc Cheng Queen Elizabeth Hospital
Use of Antiarrhythmic Drugs for AF Who, What and How? Dr. Marc Cheng Queen Elizabeth Hospital Content i. Rhythm versus Rate control ii. Anti-arrhythmic for Rhythm Control iii. Anti-arrhythmic for Rate
More informationDisclosures. Managing Atrial Fibrillation in Atrial Fibrillation: A Growing Problem. Objectives. Atrial Fibrillation: Prevalence Estimates
Managing Atrial Fibrillation in 2010 Jennifer Cummings, MD FACC Director, Cardiac Electrophysiology Akron General Medical Center Disclosures Company Boston Scientific St. Jude Medical Medtronic Sanofi-Aventis
More informationAtrial Fibrillation. Wat ur di-n 2 no. Ned Gutman 6 August, 2009
Atrial Fibrillation Wat ur di-n 2 no Ned Gutman 6 August, 2009 2 goals in treating AF Alleviation of symptoms Reduce risk of stroke Anticoagulation CHADS score Future anticoagulants Rate vs Rhythm control
More informationAtrial Fibrillation Information for patients
be informed about... Atrial Fibrillation Information for patients Atrial fibrillation (AF) is an abnormal heart rhythm. This pamphlet answers some questions you may have about AF, and gives an overview
More informationDronedarone for the treatment of non-permanent atrial fibrillation
Dronedarone for the treatment of non-permanent atrial Issued: August 2010 last modified: December 2012 guidance.nice.org.uk/ta197 NICE has accredited the process used by the Centre for Health Technology
More informationESSA HEART AND VASCULAR INSTITUTE APR/MAY/JUNE 2009 CLINICAL LETTER
CLINICAL LETTER Exciting things are happening at the ESSA Heart and Vascular Institute and the Pocono Medical Center! We are all proud of the stellar team of professionals who are working very hard to
More informationThe Emerging Atrial Fibrillation Epidemic: Treat It, Leave It or Burn It. Chandra Kumbar MD FACC FHRS The Heart Group, Evansville IN
The Emerging Atrial Fibrillation Epidemic: Treat It, Leave It or Burn It Chandra Kumbar MD FACC FHRS The Heart Group, Evansville IN Disclosures Consultant Advisory Board, Medtronic Atrial fibrillation
More informationIs cardioversion old hat? What is new in interventional treatment of AF symptoms?
Is cardioversion old hat? What is new in interventional treatment of AF symptoms? Joseph de Bono Consultant Electrophysiologist University Hospitals Birmingham Atrial Fibrillation (AF) Affects 2% of the
More informationRecent observations have focused attention on the PVs as a source of ectopic activity i determining i AF
Atrial Fibrillation in 2010 Panos Vardas Professor of Cardiology President of EHRA Atrial Fibrillation Pathophysiology of AF Triggers Recent observations have focused attention on the PVs as a source of
More informationOut with the old, in with The 2010 Atrial Fibrillation Guidelines
Out with the old, in with The 2010 Atrial Fibrillation Guidelines Kseniya Chernushkin B.Sc.(Pharm.), VCH/PHC Pharmacy Resident Mary Elliot B.Sc.(Pharm.), VCH/PHC Pharmacy Resident March 22, 2011 Outline
More informationMohammad Zubaid, MB, ChB, FRCPC, FACC
Management and one year outcome of atrial fibrillation in Middle Eastern cohort enrolled in the observational Gulf Survey of Atrial Fibrillation Events (Gulf SAFE) Mohammad Zubaid, MB, ChB, FRCPC, FACC
More informationdronedarone, 400mg, film-coated tablets (Multaq ) SMC No. (636/10) Sanofi-aventis Ltd
dronedarone, 400mg, film-coated tablets (Multaq ) SMC No. (636/10) Sanofi-aventis Ltd 6 August 2010 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises
More informationOutcomes of AF Ablation
2017 춘계심혈관통합학술대회 AF Summit: Atrial Fibrillation Apr.21(Fri) 14:40-16:10 Rm.300B 15:00-15:10 Outcomes of AF Ablation Gi-Byoung Nam MD Asan Medical Center, UUCM 2017 Annual Spring Scientific Conference of
More informationSupplementary Online Content
Supplementary Online Content Verma A, Champagne J, Sapp J, et al. Asymptomatic episodes of atrial fibrillation before and after catheter ablation: a prospective, multicenter study. JAMA Intern Med. Published
More informationIndex. cardiology.theclinics.com. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A AADs. See Antiarrhythmic drugs (AADs) ACE inhibitors. See Angiotensin-converting enzyme (ACE) inhibitors ACP in transseptal approach to
More informationScompenso cardiaco e F A : ruolo della ablazione transcatetere. Prof. Fiorenzo Gaita
Scompenso cardiaco e F A : ruolo della ablazione transcatetere Prof. Fiorenzo Gaita Patients with atrial fibrillation (%) Prevalence of AF in HF Trials 60 50 30% NYHA III-IV NYHA IV 40 NYHA II-III 30 20
More information심방세동과최신항응고요법 RACE II AFFIRM 항응고치료는왜중요한가? Rhythm control. Rate control. Anticoagulation 남기병 서울아산병원내과. Clinical Impact of Atrial Fibrillation
소강당 심방세동과최신항응고요법 남기병 서울아산병원내과 Clinical Impact of Atrial Fibrillation QoL Hospitalization Stroke CHF Mortality 항응고치료는왜중요한가? Rhythm control Rate control Anticoagulation JACC Vol. 38, No. 4, 2001 AFFIRM RACE
More informationΚατάλυση παροξυσμικής κολπικής μαρμαρυγής Ποια τεχνολογία και σε ποιους ασθενείς; Χάρης Κοσσυβάκης Καρδιολογικό Τμήμα Γ.Ν.Α. «Γ.
Κατάλυση παροξυσμικής κολπικής μαρμαρυγής Ποια τεχνολογία και σε ποιους ασθενείς; Χάρης Κοσσυβάκης Καρδιολογικό Τμήμα Γ.Ν.Α. «Γ. ΓΕΝΝΗΜΑΤΑΣ» Rhythm control antiarrhythmic drugs vs catheter ablation Summary
More informationAtrial Fibrillation Ablation: in Whom and How
Update on Consensus Statement on Management of Atrial Fibrillation: EHRA 2012 Atrial Fibrillation Ablation: in Whom and How Update of HRS/EHRA AF/ECAS Ablation Document 2012 Anne M Gillis MD FHRS Professor
More informationAtrial Fibrillation Management in the ED. J Fisher May 2014"
Atrial Fibrillation Management in the ED J Fisher May 2014" A 48 yr old man presents with palpitations. He had a big night last night with old mates. ECG How will you manage him? Why important? Common
More informationAtrial Fibrillation Cases. Dr Paul Broadhurst Consultant Cardiologist
Atrial Fibrillation Cases Dr Paul Broadhurst Consultant Cardiologist November 2011 Mr TH age 72 Routine medical for hypertension check Denies any symptoms despite close questioning PMH: hypertension, MI,
More informationDos and Don t in Cardiac Arrhythmia. Case 1 -ECG. Case 1. Management. Emergency Admissions. Reduction of TE risk -CHADS 2 score. Hospital Admissions
Emergency Admissions Dos and Don t in Cardiac Arrhythmia Tom Wong, MD, FESC Consultant Cardiologist, Honorary Senior Lecturer Royal Brompton & Harefield Hospitals National Heart and Lung Institute, Imperial
More informationAtrial Fibrillation: Catheter Ablation with New Technologies, Improving Quality of Life and Outcomes in Various Disease States
Atrial Fibrillation: Catheter Ablation with New Technologies, Improving Quality of Life and Outcomes in Various Disease States Srinivas R. Dukkipati, MD Co-Director, Cardiac Arrhythmia Service The Mount
More informationAsif Serajian DO FACC FSCAI
Anticoagulation and Antiplatelet update: A case based approach Asif Serajian DO FACC FSCAI No disclosures relevant to this talk Objectives 1. Discuss the indication for antiplatelet therapy for cardiac
More informationThe RealiseAF registry:
The RealiseAF registry: An International, observational, cross-sectional survey evaluating atrial fibrillation management and the cardiovascular risk profile of AF patients initial results PG.Steg on behalf
More informationHFpEF. April 26, 2018
HFpEF April 26, 2018 (J Am Coll Cardiol 2017;70:2476 86) HFpEF 50% or more (40-71%) of patients with CHF have preserved LV systolic function. HFpEF is an increasingly frequent hospital discharge. Outcomes
More informationMANAGING ATRIAL FIBRILLATION: BEYOND ANTICOAGULATION December 9, 2017
MANAGING ATRIAL FIBRILLATION: BEYOND ANTICOAGULATION December 9, 2017 1 Faculty Disclosure Faculty: Peter Leong-Sit MSc, MD, FRCPC, FHRS Associate Professor, Western University Cardiologist, London Heart
More informationProfessor DA Fitzmaurice Primary Care Clinical Sciences University of Birmingham
New Guidelines for SPAF Professor DA Fitzmaurice Primary Care Clinical Sciences University of Birmingham Stroke prevention and atrial fibrillation Epidemiology of atrial fibrillation How common is it?
More informationThe most common. hospitalized patients. hypotension due to. filling time Rate control in ICU patients may be difficult as many drugs cause hypotension
Arrhythmias in the critically ill ICU patients: Approach for rapid recognition & management Objectives Be able to identify and manage: Atrial fibrillation with a rapid ventricular response Atrial flutter
More informationThe pill-in-the-pocket strategy for paroxysmal atrial fibrillation
The pill-in-the-pocket strategy for paroxysmal atrial fibrillation KONSTANTINOS P. LETSAS, MD, FEHRA LABORATORY OF CARDIAC ELECTROPHYSIOLOGY EVANGELISMOS GENERAL HOSPITAL OF ATHENS ARRHYTHMIAS UPDATE,
More informationΚΟΛΠΙΚΗ ΜΑΡΜΑΡΥΓΗ ΦΑΡΜΑΚΕΥΤΙΚΗ ΗΛΕΚΤΡΙΚΗ ΑΝΑΤΑΞΗ. ΣΠΥΡΟΜΗΤΡΟΣ ΓΕΩΡΓΙΟΣ Καρδιολόγος, Ε/Α, Γ.Ν.Κατερίνης. F.E.S.C
ΚΟΛΠΙΚΗ ΜΑΡΜΑΡΥΓΗ ΦΑΡΜΑΚΕΥΤΙΚΗ ΗΛΕΚΤΡΙΚΗ ΑΝΑΤΑΞΗ ΣΠΥΡΟΜΗΤΡΟΣ ΓΕΩΡΓΙΟΣ Καρδιολόγος, Ε/Α, Γ.Ν.Κατερίνης. F.E.S.C Definitions of AF: A Simplified Scheme Term Definition Paroxysmal AF AF that terminates
More information